1. Home
  2. GKOS vs VNT Comparison

GKOS vs VNT Comparison

Compare GKOS & VNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • VNT
  • Stock Information
  • Founded
  • GKOS 1998
  • VNT 2019
  • Country
  • GKOS United States
  • VNT United States
  • Employees
  • GKOS N/A
  • VNT N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • VNT Industrial Machinery/Components
  • Sector
  • GKOS Health Care
  • VNT Industrials
  • Exchange
  • GKOS Nasdaq
  • VNT Nasdaq
  • Market Cap
  • GKOS 5.1B
  • VNT 4.4B
  • IPO Year
  • GKOS 2015
  • VNT N/A
  • Fundamental
  • Price
  • GKOS $89.91
  • VNT $34.86
  • Analyst Decision
  • GKOS Strong Buy
  • VNT Buy
  • Analyst Count
  • GKOS 13
  • VNT 7
  • Target Price
  • GKOS $135.15
  • VNT $42.80
  • AVG Volume (30 Days)
  • GKOS 1.1M
  • VNT 1.0M
  • Earning Date
  • GKOS 04-30-2025
  • VNT 05-01-2025
  • Dividend Yield
  • GKOS N/A
  • VNT 0.29%
  • EPS Growth
  • GKOS N/A
  • VNT N/A
  • EPS
  • GKOS N/A
  • VNT 2.46
  • Revenue
  • GKOS $404,523,000.00
  • VNT $2,964,300,000.00
  • Revenue This Year
  • GKOS $27.84
  • VNT $2.45
  • Revenue Next Year
  • GKOS $27.88
  • VNT $4.72
  • P/E Ratio
  • GKOS N/A
  • VNT $14.21
  • Revenue Growth
  • GKOS 23.92
  • VNT N/A
  • 52 Week Low
  • GKOS $77.10
  • VNT $27.22
  • 52 Week High
  • GKOS $163.71
  • VNT $41.61
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 45.80
  • VNT 68.82
  • Support Level
  • GKOS $84.26
  • VNT $33.06
  • Resistance Level
  • GKOS $92.27
  • VNT $33.95
  • Average True Range (ATR)
  • GKOS 3.94
  • VNT 0.89
  • MACD
  • GKOS 0.57
  • VNT 0.57
  • Stochastic Oscillator
  • GKOS 58.87
  • VNT 91.82

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About VNT Vontier Corporation

Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.

Share on Social Networks: